Health · Medical Research · 3 hrs ago
Gilead pill improves remission rates in mid-stage ulcerative colitis trial
Gilead Sciences reported encouraging results from a mid-stage study of its oral drug emvistegrast for ulcerative colitis.
The 200-milligram daily dose improved remission rates compared with a placebo after 12 weeks of treatment.
The study involved people with moderate to severe ulcerative colitis, a form of inflammatory bowel disease.
The improvement was 23% beyond placebo, and the result was statistically significant.
Existing treatments are available, but many patients still have symptoms and do not reach remission.
The results could strengthen Gilead’s effort to develop medicines for inflammatory and autoimmune conditions; no next study or regulatory step was specified.
Gilead Sciences’ oral drug emvistegrast showed a statistically significant benefit for people with moderate to severe ulcerative colitis in a Phase 2 study.
A 200 milligram daily dose taken for 12 weeks produced a 23% placebo-adjusted clinical remission rate.
The result exceeded Wall Street analyst expectations, according to STAT.
Gilead said the findings encouraged it as it develops medicines for inflammatory diseases.
- Who
- Gilead Sciences and patients with moderate to severe ulcerative colitis.
- What
- Gilead’s emvistegrast showed a 23% placebo-adjusted clinical remission rate in a Phase 2 study.
- When
- The study results were reported on Monday, October 19, 2026.
- Where
- Not stated.
- Why
- The study assessed emvistegrast as a treatment for ulcerative colitis.
This story does not have two clearly opposing sides.
Patients taking a 200 milligram daily dose of emvistegrast were treated over this period.
STAT reported the Phase 2 study results.
- Drug
- Emvistegrast
- Daily dose
- 200 milligrams
- Treatment period
- 12 weeks
- Placebo-adjusted clinical remission rate
- 23%
- Study phase
- Phase 2
3 sources
What people are saying
Emvistegrast has the potential to be a best-in-class oral for patients with ulcerative colitis
Patients with inflammatory bowel disease, while they have other therapies available, still have persistent symptoms. A majority do not achieve remission, so seeing these data was encouraging for us.